Antony Maniatis, MD
Gastroenterology · Jacksonville, FLNPI 1942292099
Payments from drug & device makers
Across 804 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$1K
- Gilead$742
- Madrigal Pharmaceuticals$677
- plus $5K from 26 others
What the payments were for
- Food & beverage$13,67998%
- Education$2122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 259 | $4,136 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 78 | $1,245 |
| Takeda Pharmaceuticals U.S.A., Inc. | 69 | $1,087 |
| Johnson & Johnson(2 entities) | 56 | $1,056 |
| Gilead | 40 | $742 |
| Madrigal Pharmaceuticals | 37 | $677 |
| Sanofi | 27 | $552 |
| Regeneron Healthcare Solutions, Inc. | 26 | $552 |
| QOL Medical, LLC | 19 | $534 |
| Bristol Myers Squibb | 36 | $525 |
| Pfizer | 31 | $511 |
| Merck | 23 | $415 |
| Aimmune Therapeutics, Inc. | 16 | $297 |
| Phathom Pharmaceuticals, Inc. | 13 | $276 |
| Lilly USA, LLC | 13 | $235 |
| Ardelyx, Inc. | 9 | $163 |
| Redhill Biopharma Inc. | 8 | $129 |
| Ironwood Pharmaceuticals, Inc | 8 | $124 |
| Intercept Pharmaceuticals, Inc. | 6 | $97 |
| Enterra Medical, Inc. | 4 | $95 |
| Shionogi Inc | 6 | $90 |
| Alnylam Pharmaceuticals Inc. | 3 | $83 |
| Amgen | 3 | $61 |
| Nestle Healthcare Nutrition Inc. | 4 | $57 |
| Vivus LLC | 2 | $37 |
| Ferring Pharmaceuticals Inc. | 2 | $25 |
| Novo Nordisk | 1 | $24 |
| Evoke Pharma, Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Shire North American Group Inc | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $13 |
| Romark Laboratories, LC | 1 | $1 |
How this compares
$13,891 in reported general payments places this provider in the 75th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 13 | $354,471 |
| XifaxanRifaximin | 57 | $192,338 |
| LinzessLinaclotide | 113 | $90,420 |
| TrulancePlecanatide | 55 | $44,358 |
| RelistorMethylnaltrexone Bromide | 12 | $28,297 |
| MotegrityPrucalopride Succinate | 27 | $17,866 |
| MovantikNaloxegol Oxalate | 23 | $12,081 |
| Mesalamine | 24 | $8,065 |
| Dexlansoprazole DrDexlansoprazole | 21 | $7,903 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 125 | $7,366 |
| CholestyramineCholestyramine (With Sugar) | 43 | $3,888 |
| Ursodiol | 22 | $3,885 |
| Colesevelam Hcl | 36 | $3,580 |
| Pantoprazole Sodium | 325 | $3,493 |
| Mesalamine ErMesalamine | 17 | $3,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,056 | $354,47113 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Relistor | $1,245 | $264,993124 claims |
| AbbVieLinzess | $4,136 | $90,420113 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,087 | $17,86627 claims |
| Redhill Biopharma Inc.Movantik | $129 | $12,08123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Jacksonville
- Mark FleisherJacksonville$1.3M
- Bharat MisraJacksonville$853K
- Francis FarrayeJacksonville$797K
- Vivek KumbhariJacksonville$761K
- Ali Moghani LankaraniJacksonville$713K
- Howard SchwartzTavernier$38.8M
- Guy NeffSarasota$17.6M
- Syed LateefClermont$6.4M
- Jeffrey SchneiderCoral Springs$6M
- Zaid RanaMiami$5.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.